Compositions and methods to improve anti-angiogenic therapy and immunotherapy

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11279765
APP PUB NO 20200216549A1
SERIAL NO

16628941

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Agents that inhibit CX3CL1 in endothelial cells to reduce or inhibit immunosuppression mechanisms that are co-opted by cancer cells to evade host immune system, and that reduce immunosuppression in context of therapies that target VEGF-dependent signaling, and methods of use thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE GENERAL HOSPITAL CORPORATION55 FRUIT ST BOSTON MA 02114

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fukumura, Dai Newton, US 19 156
Jain, Rakesh K Wellesley, US 48 354
Jung, Keehoon Boston, US 5 47

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 22, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 22, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 22, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00